Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …

Therapies targeting late events in Alzheimer's disease (AD), including aggregation of
amyloid beta (Aβ) and hyperphosphorylated tau, have largely failed, probably because they …

Aducanumab has been approved by the US Food and Drug Administration for treatment of
Alzheimer's disease (AD). Clinicians require guidance on the appropriate use of this new …

Alzheimer's disease (AD) pathologies were discovered in the accessible neurosensory
retina. However, their exact nature and topographical distribution, particularly in the early …

Current technological advancements in clinical and research settings have permitted a more
intensive and comprehensive understanding of Alzheimer's disease (AD). This development …

BACKGROUND. Noninvasive detection of Alzheimer's disease (AD) with high specificity and
sensitivity can greatly facilitate identification of at-risk populations for earlier, more effective …

Glia are essential for brain functioning during development and in the adult brain. Here, we
discuss the various roles of both microglia and astrocytes, and their interactions during brain …

Topic OCT is a noninvasive tool to measure specific retinal layers in the eye. The
relationship of retinal spectral-domain (SD) OCT measurements with Alzheimer's disease …

Microglia, the immunocompetent cells of the central nervous system (CNS), act as
neuropathology sensors and are neuroprotective under physiological conditions. Microglia …

Studies of rodent models of Alzheimer's disease (AD) and of human tissues suggest that the
retinal changes that occur in AD, including the accumulation of amyloid beta (Aβ), may serve …